150,351 members

Skip to content. | Skip to navigation

News

New guidance on diagnosing bowel conditions is pathway to significant financial savings

 

Start sharing

If you've got news you'd like to share, let us know and we'll consider it for our news section.
 

New guidance on diagnosing bowel conditions is pathway to significant financial savings

A new national care pathway to help clinicians quickly and simply to distinguish patients with irritable bowel syndrome (IBS) from those with inflammatory bowel disease (IBD) has been developed, in a move that could result in significant cost savings.

The pathway encourages primary care clinicians to use faecal calprotectin testing as a decision diagnostic, helping to reduce uncertainty for patients as well as the number of unnecessary costly hospital referrals for further invasive and unpleasant testing.

Patients should benefit from improved diagnosis, treatment and management, as well as earlier identification of more serious conditions. CCGs also stand to benefit from substantial savings by preventing unnecessary referrals to secondary care.